CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lower our 12-month price target to $190 from $210, a 14.8x multiple of our 2026 EPS estimate (unchanged at $12.80; 2027 estimate up $0.07 to $14.19), below IQV's one-and-three year historical forward averages of 15.6x and 18.3x, respectively. We think headwinds may persist across key life sciences end markets due to macroeconomic pressures, uncertain tariff and research funding policy, and weaker biotech spending and clinical trial activity. Positively, we think IQV benefits from its diversification compared with peers, with significant earnings coming from health care technology and analytics, as well as contract research and commercialization services. We think recent bookings figures indicate a gradually improving biopharma spending environment despite the macroeconomic headwinds, though there could be a multi-quarter lag effect for emerging biopharma funding to flow through to IQV's bookings, based on company commentary at the recent Bank of America Global Healthcare Conference.